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University of Glasgow, Glasgow, United Kingdom; and 9R&D Group VitaK, Maastricht University, Maastricht, The NetherlandsIntroduction: Sequencing peptides included in the urinary proteome identiﬁes the parent proteins and
may reveal mechanisms underlying the pathophysiology of chronic kidney disease.
Methods: In 805 randomly recruited Flemish individuals (50.8% women; mean age, 51.1 years), we
determined the estimated glomerular ﬁltration rate (eGFR) from serum creatinine using the Chronic
Kidney Disease Epidemiology Collaboration (CKD-EPI) equation. We categorized eGFR according to the
National Kidney Foundation Kidney Disease Outcomes Quality Initiative guideline. We analyzed
74 sequenced urinary peptides with a detectable signal in more than 95% of participants. Follow-up
measurements of eGFR were available in 597 participants.
Results: In multivariable analyses, baseline eGFR decreased (P# 0.022) with urinary fragments of mucin-1
(standardized association size expressed in ml/min/1.73 m2, 4.48), collagen III (2.84), and ﬁbrinogen
(1.70) and was bi-directionally associated (P # 0.0006) with 2 urinary collagen I fragments (þ2.28
and 3.20). The eGFR changes over 5 years (follow-up minus baseline) resulted in consistent estimates
(P # 0.025) for mucin-1 (1.85), collagen (1.37 to 1.43) and ﬁbrinogen (1.45) fragments. Relative risk of
having or progressing to eGFR <60 ml/min/1.73 m2 was associated with mucin-1. Partial least-squares
analysis conﬁrmed mucin-1 as the strongest urinary marker associated with decreased eGFR, with a
score of 2.47 compared with 1.80 for a collagen I fragment as the next contender. Mucin-1 predicted eGFR
decline to <60 ml/min/1.73 m2 over and above microalbuminuria (P ¼ 0.011) and retained borderline
signiﬁcance (P ¼ 0.05) when baseline eGFR was accounted for.
Discussion: In the general population, mucin-1 subunit a, an extracellular protein that is shed from renal
tubular epithelium, is a novel biomarker associated with renal dysfunction.
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International Reports (2017) 2, 811–820estimated that worldwide 0.40 million of nearly 50
million deaths occurring annually were attributable
to CKD in 1990 and 0.74 million in 2010, representing
an increase by 82.3%.1 In the United States, the
prevalence of CKD, deﬁned as an estimated glomer-
ular ﬁltration rate (eGFR) < 60 ml/min/1.73 m2, rose
from 10.0% in 1988 to 1994 to 13.1% in 1999 to
2004.2 The International Society of Nephrology
appealed to address knowledge gaps related to
kidney injury.3811
CLINICAL RESEARCH Z-Y Zhang et al.: Mucin-1 as Urinary Biomarker of eGFR DeclineAs recently reviewed,4 proteins mainly appear in
urine when the glomerular barrier is failing. In
contrast, peptides are freely ﬁltered into urine and, if
incompletely reabsorbed by the tubules, the urinary
excretion of peptides captures the early stages of renal
dysfunction.5 Capillary electrophoresis coupled with
high-resolution mass spectrometry enables detection of
more than 5000 peptide fragments in urine samples.6,7
We recently identiﬁed a unique urinary proteomic
signature, which, in patient cohorts,8–10 reproducibly
predicted progression of CKD, independent of other
risk factors. To deepen insight in the pathophysiolog-
ical pathways leading to renal injury and to extend
previous ﬁndings in patients8–10 to the general popu-
lation, we analyzed the database of the Flemish Study
on Environment, Genes and Health Outcomes (FLE-
MENGHO)11 and searched for association of eGFR with
individual urinary peptide fragments, of which the
amino acid sequence revealed the parent protein.
MATERIALS AND METHODS
Recruitment of Participants
FLEMENGHO complies with the Declaration of Hel-
sinki12 for research in human subjects. The Ethics
Committee of the University of Leuven approved the
study.11 All participants gave informed written con-
sent. Recruitment started in 1985 and continued until
2004. The initial participation rate was 78.0%. The
participants were repeatedly followed up at the ﬁeld
center in the catchment area (North Limburg, Belgium).
From May 2005 until May 2010, we mailed an invita-
tion letter to 1208 former participants for a follow-up
examination. However, 153 were unavailable, because
they had died (n ¼ 26), had been institutionalized or
were too ill (n ¼ 27), or had moved out of the area (n ¼
100). Of the remaining 1055 former participants, 828
(78.5%) renewed informed consent. We excluded 23
participants from analysis because urine samples were
unavailable (n ¼ 23). Thus, the number of participants
statistically analyzed totaled 805.
Assessment of Renal Function
Venous blood samples were drawn after at least 8 hours
of fasting. We measured the concentration of creatinine
in serum, using the Jaffe method13 with modiﬁcations
described elsewhere,14,15 in a single certiﬁed laboratory
that applied isotope-dilution mass spectrometry for
calibration of the serum creatinine measurements. We
derived eGFR from serum creatinine by the Chronic
Kidney Disease Epidemiology Collaboration (CKD-EPI)16
equation. The CKD stages, deﬁned according to the
National Kidney Foundation Kidney Disease Outcomes
Quality Initiative (KDOQI) guideline, were eGFR$ 90, 60
to 89, 30 to 59, 15 to 29, and < 15 ml/min/1.73 m2 for812stages 1, 2, 3, 4, and 5, respectively. eGFRwas assessed at
baseline in all participants, of whom 597 had a follow-up
assessment (Supplementary Figure S1). Participants also
collected a 24-hour urine sample within 1 week of the
baseline clinical examination at the ﬁeld center for mea-
surement of microalbuminuria and creatinine. Micro-
albuminuria was deﬁned as an albumin-to-creatinine
ratio of$ 3.5 mg/mmol in women and$ 2.5 mg/mmol in
men, and macroalbuminuria as an albumin-to-creatinine
ratio of $ 30 mg/mmol.17 Guideline-based18 staging of
CKD requires repeated measurement of eGFR or albu-
minuria or additional evidence for renal disease. How-
ever, as this is impracticable in the context of population
studies, because multiple visits decrease the participa-
tion rate, staging of CKD at baseline and follow-up relied
in our current study, as often done in landmark epide-
miological research,19–22 on a single serum sample.
At baseline, we also measured plasma glucose, serum
total and high-density lipoprotein (HDL) cholesterol,
serum g-glutamyltransferase as index of alcohol intake,
and 24-hour microalbuminuria. Diabetes mellitus was a
self-reported diagnosis, a fasting plasma glucose
of $126 mg/dl, or use of antidiabetic agents.23
Measurements of Biomarkers
Aliquots (0.7 ml) were stored at –80 C and thawed
immediately before analysis. Capillary electrophoresis
coupled with high-resolution mass spectrometry anal-
ysis, sequencing of peptides, mass spectrometry data
evaluation, and calibration were performed, as
described in detail in the Supplementary Material and
in previous publications.6,7 A total of 2129 urinary
peptides were sequenced. We selected 74 peptides
(Supplementary Table S5), which had a detectable signal
in more than 95% of participants (Supplementary
Figure S2). For the current analysis, the values of pep-
tides undetectable in less than 5% of randomly varying
study participants were set to the minimum of the dis-
tribution of each sequenced peptide. This strategy has
been validated by other research groups.24,25
Other Measurements
Blood pressure was the average of 5 consecutive
auscultatory readings obtained according to European
guidelines26 with a standard mercury sphygmoma-
nometer after participants had rested in the sitting
position for at least 10 minutes. Hypertension was a
blood pressure of at least 140 mm Hg systolic or 90
mm Hg diastolic or use of antihypertensive drugs.
Body mass index was calculated as weight in kilograms
divided by height in meters squared. Study nurses
administered a standardized questionnaire inquiring
into each participant’s medical history, smoking and
drinking habits, and intake of medications.Kidney International Reports (2017) 2, 811–820
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For database management and statistical analysis, we
used SAS version 9.4 (SAS Institute Inc., Cary, NC).
Supplementary Table S1 summarizes the statistical
analysis work ﬂow. Means were compared using the
large-sample z test, proportions by the Fisher exact
test, and survival function estimates by the log-rank
test. We normalized the distributions of g-glutamyl-
transferase and 24-hour albuminuria by a logarithmic
transformation. We rank normalized the distributions
of the urinary peptides by sorting measurements from
the smallest to the largest and then applying the in-
verse cumulative normal function.27
We identiﬁed covariables to be retained in the ana-
lyses by a best-subset approach, with the number of
covariables allowed to be retained in the model set at
11. In continuous analyses, we standardized eGFR to
the average in the whole study population (mean or
ratio) of the covariables identiﬁed by stepwise regres-
sion. While accounting for covariables, we regressed
the indices of renal function on the urinary peptide
markers and constructed –log10 probability plots.
Based on the number of parent proteins, we used a
Bonferroni-corrected P-value threshold of 0.005 (0.05/
10). Renal function and changes in renal function were
analyzed as continuous or categorical variables, using
multivariable-adjusted linear regression, logistic
regression, and Cox modeling, as appropriate. In Cox
regression, the start date to event and censoring date
coincided with the baseline and follow-up visit.
In the next step of our analyses, we applied partial
least-squares (PLS) analysis, which is a statistical
technique that constructs models for continuous out-
comes in relation to correlated high-dimensional
explanatory variables.28 In our study, PLS allowed
identiﬁcation of a set of independent latent factors that
are linear combinations of the urinary peptides and
that maximize the covariance between the urinary
peptides and the variables describing renal function.
We studied the multivariable-adjusted eGFR in relation
to the latent factors. We retained the smallest number
of latent factors for which the predicted residual sums
of squares (calculated using leave-one-out cross-vali-
dation) did not differ signiﬁcantly (P > 0.10) from the
model with the minimum predicted residual sums of
squares value as assessed by the van der Voet T2 sta-
tistic. The importance of each urinary peptide in the
construction of the PLS factors was assessed from the
Variable Importance in Projection (VIP) scores of Wold,
with the threshold set at 1.5. Finally, we evaluated the
capability to discriminate between participants with or
without renal impairment by constructing receiver
operating characteristic curves and by calculating the
area under the receiver operating characteristic curveKidney International Reports (2017) 2, 811–820(AUC). The 95% conﬁdence interval (CI) of the AUC
was calculated by the DeLong method.
RESULTS
Baseline Characteristics of Participants
Of 805 participants, 409 (50.8%) were female. All were
Europeans of white ethnicity. Mean values ( SD) in
the 805 participants were 51.1  15.7 years for age,
26.5  4.3 kg/m2 for body mass index, 129.5  17.7
mm Hg for systolic blood pressure, 79.7  9.6 mm Hg
for diastolic blood pressure, and 203  38 and 55  14
mg/dl for total and HDL cholesterol. Among all par-
ticipants, 344 (42.7%) had hypertension, of whom 212
(61.6%) were on antihypertensive drug treatment, and
20 (2.5%) had diabetes.
At baseline, the prevalence of renal dysfunction,
deﬁned as an eGFR of < 60 ml/min/1.73 m2, amounted
to 74 (9.2%). Table 1 shows that age, body mass index,
central obesity, systolic and mean arterial pressure,
total cholesterol, plasma glucose, urinary albumin-to-
creatinine ratio, 24-hour albuminuria, proportion of
women, prevalence of hypertension, and probability of
being treated for hypertension were all higher (P #
0.028) in participants with renal dysfunction. The
opposite was the case for the prevalence of reported
alcohol intake and serum HDL cholesterol levels (P #
0.049). Reduced eGFR was associated with a higher
prevalence of microalbuminuria (18 participants [2.5%]
vs. 11 participants [14.9%]; P < 0.0001), with no dif-
ference in the prevalence of macroalbuminuria
(1 [0.1%] vs. 1 [1.4%] participant; P ¼ 0.18). Compared
with participants with normal renal function, patients
with renal dysfunction more frequently (P < 0.0001)
used diuretics (8.3% vs. 33.8%), b-blockers (13.1% vs.
40.5%), angiotensin-converting enzyme inhibitors, and
angiotensin-I type-1 receptor blockers (7.4% vs.
21.6%), whereas this was not the case for vasodilators,
including calcium-channel blockers and a-blockers
(4.7% vs. 8.1%; P ¼ 0.19). The baseline characteristics
of the 597 participants who had a follow-up measure-
ment of eGFR appear in Supplementary Table S2 and
mirror those presented in Table 1.
Change in eGFR and eGFR Category
Median follow-up of eGFR in 597 participants was 4.7
years (5th to 95th percentile interval, 3.7–5.4). In these
participants, eGFR decreased by 1.5 ml/min/1.73 m2
per year. Of 172 participants with baseline eGFR $ 90
ml/min/1.73 m2, 75 (43.6%) maintained this category,
and 97 (56.4%) progressed to eGFR 60–89 ml/min/1.73
m2. Of the 386 participants with baseline eGFR 60–89
ml/min/1.73 m2, 21 participants (5.4%) regressed to
eGFR $ 90 ml/min/1.73 m2, 309 (80.1%) remained
within this category, and 55 (14.2%) and 1 (0.3%)813
Table 1. Baseline characteristics of participants by renal function
Characteristic All eGFR < 60 eGFR ‡ 60 P value
No. of participants (%)
All participants in category 805 731 74
Women 409 (50.8) 359 (49.1) 50 (67.6) 0.003
Smokers 162 (20.1) 153 (20.9) 9 (12.2) 0.073
Drinking $ 5 g/d alcohol 328 (40.7) 314 (43.0) 14 (9.2) <0.0001
Hypertension 344 (42.7) 285 (39.0) 59 (79.7) <0.0001
Antihypertensive treatment 212 (61.6) 165 (22.6) 47 (63.5) <0.0001
Diabetes mellitus 20 (2.5) 16 (2.2) 4 (5.4) 0.090
Mean (SD) of characteristic
Age (yr) 51.1  15.7 49.1  14.8 70.6  10.4 <0.0001
Body mass index (kg/m2) 26.5  4.3 26.4  4.4 27.8  3.8 0.008
Waist-to-hip ratio 0.87  0.08 0.86  0.08 0.89  0.08 0.013
Systolic pressure (mm Hg) 129.5  17.7 127.8  16.3 145.8  21.9 <0.0001
Diastolic pressure (mm Hg) 79.7  9.6 79.6  9.7 80.2  8.1 0.55
Mean arterial pressure (mm Hg) 96.3  10.7 95.7  10.6 102.1  10.0 <0.0001
Heart rate (beats/min) 63.5  9.8 63.5  9.7 63.7  10.7 0.82
Serum total cholesterol (mg/dl) 203  38 202  37 215  39 0.006
Serum HDL cholesterol (mg/dl) 55  14 55  14 52  13 0.049
Plasma glucose (mg/dl) 87  14 88  14 92  13 0.028
Serum creatinine (mg/dl) 0.95  0.18 1.00  0.14 1.19  0.29 <0.0001
eGFR (ml/min/1.73 m2) 81.8  17.3 77.9  14.0 51.3  7.2 <0.0001
Geometric mean (IQR) of characteristic
UACR (mg/mmol) 0.52 (0.32–0.76) 0.49 (0.30–0.72) 1.06 (0.48–1.28) <0.0001
24-h Albuminuria (mg) 6.0 (4.1–7.4) 5.8 (4.1–7.1) 9.3 (4.6–9.5) <0.0001
g-Glutamyltransferase (units/l) 23 (15–32) 23 (15–32) 25 (16–33) 0.42
eGFR, estimated glomerular ﬁltration rate, derived from serum creatinine by the Chronic Kidney Disease Epidemiology Collaboration equation; HDL, high-density lipoprotein; IQR,
interquartile range; UACR, urinary albumin-to-creatinine ratio. Values are arithmetic mean (SD) or geometric mean (interquartile range). Ofﬁce blood pressure was the average of 5
consecutive readings. Hypertension was deﬁned as an ofﬁce blood pressure $ 140 mm Hg systolic or $ 90 mm Hg diastolic or use of antihypertensive drugs. Diabetes mellitus was a
self-reported diagnosis, a fasting glucose level $ 126 mg/dl, or use of antidiabetic agents.
CLINICAL RESEARCH Z-Y Zhang et al.: Mucin-1 as Urinary Biomarker of eGFR Declineprogressed to eGFR 30–59 or 15–29 ml/min/1.73 m2,
respectively. Of the 39 participants with baseline eGFR
30 to 59 ml/min/1.73 m2, 9 participants (23.1%)
regressed to eGFR 60 to 89 ml/min/1.73 m2, 26 (66.7%)
remained at the same stage, and 4 (10.3%) progressed
to eGFR 15 to 29 ml/min/1.73 m2. No participant pro-
ceeded to the eGFR category < 15 ml/min/1.73 m2 or to
renal replacement therapy.
Analysis of eGFR as Continuous Variable
Based on the best-subset regression procedure, we
adjusted the cross-sectional associations between eGFR
and the urinary peptides in 805 participants for mean
arterial pressure, waist-to-hip ratio, smoking, plasma
glucose, g-glutamyltransferase, total-to-HDL cholesterol
ratio, 24-hour albuminuria and use of diuretics,
inhibitors of the renin-angiotensin system (b-blockers,
angiotensin-converting enzyme inhibitors, and angio-
tensin type-1 receptor blockers) and vasodilators
(calcium-channel blockers and a-blockers). These cova-
riables explained 21.9% of the variance in eGFR.
Analyses with change in eGFR in 597 participants were
additionally adjusted for baseline eGFR and follow-up
duration.
Supplementary Table S3 lists the multivariable-
adjusted associations of eGFR and change in eGFR814with the urinary peptides measured at baseline.
Figure 1 identiﬁes the peptides that retained signiﬁ-
cance with Bonferroni correction applied. Table 2 lists
the urinary peptides that, with adjustment for multiple
testing, were associated with both baseline eGFR and
change in eGFR over follow-up. Per 1-SD increment in
the urinary peptides (Table 2), the association sizes,
expressed in ml/min/1.73 m2, amounted to 4.48
(P < 0.0001) for p8342 (mucin-1), 3.20 (P < 0.0001)
for p77763 (collagen I), 2.84 (P < 0.0001) for p105352
(collagen III), 1.70 (P ¼ 0.022) for p61573 (ﬁbrin-
ogen), and þ2.28 (P ¼ 0.0006) for p57531 (collagen I).
Consistent with the cross-sectional analysis, over time
(Table 2), eGFR increased with p57531 (þ1.43 ml/min/
1.73 m2 per 5 years; P ¼ 0.005) but decreased with the
other urinary peptides, with effect sizes ranging from
–1.23 to –1.85 ml/min/1.73 m2 per 5 years; P # 0.025),
among which p8342 (mucin-1) was the strongest
predictor.
The PLS procedure yielded 3 latent factors that
accounted for 20.1% of the overall variance in the
urinary peptides and 28.9% of the variance in
multivariable-adjusted eGFR. Figure 2 depicts the PLS-
derived VIP scores versus the centered and rescaled
correlation coefﬁcients. The dependent variable in this
analysis was baseline eGFR standardized for theKidney International Reports (2017) 2, 811–820
Figure 1. Log10(p) probability plot of the multivariable-adjusted
associations of renal function measures with the urinary peptides.
All analyses were adjusted for mean arterial pressure, waist-to-hip
ratio, smoking, plasma glucose, g-glutamyltransferase, total-to–
high-density-lipoprotein cholesterol ratio, 24-hour albuminuria, and
use of diuretics, inhibitors of the renin-angiotensin system (b-
blockers, angiotensin-converting enzyme inhibitors, and angiotensin
type-1 receptor blockers), and vasodilators (calcium-channel
blockers and a-blockers). The longitudinal analysis of change in
estimated glomerular ﬁltration rate (eGFR) as continuous variable
was additionally adjusted for baseline eGFR and follow-up duration.
The horizontal line denotes the signiﬁcance level with Bonferroni
correction applied. Red dots represent mucin-1 and green dots the
other peptides listed in Tables 2 and 3.
Figure 2. V-plots generated by partial least-squares analysis. Vari-
able Importance in Projection (VIP) scores indicate the importance of
each urinary fragment in the construction of the partial least-squares
factors and are plotted against the centered and rescaled correlation
coefﬁcients. The correlation coefﬁcients reﬂect the associations of
the multivariable-adjusted estimated glomerular ﬁltration rate (eGFR)
with the urinary fragments. Fragments associated with reduced eGFR
(left side of the V-plot) include, among others, p8342 and p77763
(Table 2). p35339 was associated with a higher eGFR (right side of the
V-plot). Colors identify fragments derived from collagens I (blue), II
(gray), III (red), IV (brown), the mucin-1 subunit a (orange), fibrinogen
(green), protocadherin-12 (purple), retinol-binding protein 4 (pink),
stabilin-2 (yellow), and uromodulin (black).
Z-Y Zhang et al.: Mucin-1 as Urinary Biomarker of eGFR Decline CLINICAL RESEARCHaforementioned covariables. The urinary peptides
associated with lower eGFR (left side of the V plot in
Figure 2) included, among others, mucin-1 subunit aTable 2. Multivariable-adjusted associations of eGFR with urinary
proteomic biomarkers
Biomarker
(baseline)
Parent
protein
eGFR baseline (n [ 805) eGFR change over 5 yr (n [ 597)
Estimate (95% CI) Estimate (95% CI)
p8342 mucin-1 –4.48 (–6.00 to –2.96)a –1.85 (–3.03 to –0.66)b
p57531 collagen I 2.28 (0.69 to 3.87)b 1.43 (0.29 to 2.57)d
p77763 collagen I –3.20 (–4.73 to –1.68)a –1.37 (–2.49 to –0.26)d
p105352 collagen III –2.84 (–4.40 to –1.27)a –1.23 (–2.38 to –0.10)c
p61573 ﬁbrinogen –1.70 (–3.26 to –0.15)c –1.45 (–2.56 to –0.33)d
eGFR, estimated glomerular ﬁltration rate, derived from serum creatinine by the Chronic
Kidney Disease Epidemiology Collaboration equation. Change in eGFR was the follow-up
minus the baseline value. Estimates given with 95% conﬁdence interval, express the
change in the dependent variable associated with a 1-SD increase in the normalized
urinary peptides measured at baseline. The cross-sectional analyses were adjusted for
mean arterial pressure, waist-to-hip ratio, smoking, plasma glucose, g-glutamyl-
transferase, total-to–high-density lipoprotein cholesterol ratio, 24-hour albuminuria, and
use of diuretics, inhibitors of the renin-angiotensin system (b-blockers, angiotensin-
converting enzyme inhibitors, and angiotensin type-1 receptor blockers) and vasodila-
tors (calcium-channel blockers and a-blockers). Longitudinal analyses were additionally
adjusted for baseline eGFR and follow-up duration. P values reflect Bonferroni-
corrected significance of the associations.
aP # 0.0001.
bP # 0.001.
cP # 0.05.
dP # 0.01.
Kidney International Reports (2017) 2, 811–820(p8342) and collagen I (p77763). The urinary peptide
associated with higher eGFR (right side of the V plot in
Figure 2) was collagen I fragment (p35339).
Analysis of eGFR Categories
Supplementary Table S4 lists the multivariable-adjusted
associations of eGFR categories ($ 60 vs. < 60 ml/min/
1.73 m2) or longitudinal change in eGFR categories
(from $ 60 to < 60 ml/min/1.73 m2) with the urinary
peptides measured at baseline. Figure 1 shows the
peptides that retained signiﬁcance with Bonferroni
correction applied. In the cross-sectional analysis
(Table 3), the odds ratios associated with a 1-SD incre-
ment in the urinary peptides were 2.03 (P < 0.0001) for
p8342 (mucin-1), 0.58 (P ¼ 0.0002) for p57531 (collagen
I), 1.45 (P ¼ 0.043) for p77763 (collagen I), 2.18
(P < 0.0001) for p105352 (collagen III), and 1.18
(P > 0.99) for p61573 (ﬁbrinogen). The risk of eGFR
decline from $ 60 to < 60 ml/min/1.73 m2 increased
(P < 0.0001) across thirds of the mucin-1 distribution
(Figure 3). With multivariable adjustments applied, the
hazard ratios associated with a 1-SD increase were 2.10
(P < 0.0001) for p8342, 0.78 (P ¼ 0.76) for p57531, 1.78
(P¼ 0.0017) for p77763, 1.16 (P> 0.99) for p105352, and
1.66 (P ¼ 0.007) for p61573 (Table 3).815
Table 3. Multivariable-adjusted associations of eGFR category with
urinary proteomic biomarkers
Biomarker
(baseline)
Parent
protein
eGFR ‡ 60 versus < 60
(731 versus 74)
eGFR ‡ 60/ < 60
(502 versus 56)
Odds ratio (95% CI) Hazard ratio (95% CI)
p8342 mucin-1 2.03 (1.34–3.08)a 2.10 (1.39–3.17)a
p57531 collagen I 0.58 (0.39–0.87)b 0.78 (0.52–1.16)
p77763 collagen I 1.45 (1.01–2.10)c 1.78 (1.16–2.73)d
p105352 collagen III 2.18 (1.42–3.34)a 1.16 (0.74–1.80)
p61573 ﬁbrinogen 1.18 (0.80–1.72) 1.66 (1.09–2.52)d
eGFR, estimated glomerular ﬁltration rate. Hazard ratios were computed excluding 39
participants with eGFR < 60 ml/min/1.73 m2 at baseline. The letter n indicates the
number of participants with eGFR $ 60 and < 60 ml/min/1.73 m2 in the cross-sectional
(odds ratio) and longitudinal (hazard ratio) analyses. The censoring date in Cox
regression coincided with the follow-up visit. All analyses were adjusted for baseline
variables, including mean arterial pressure, waist-to-hip ratio, smoking, plasma glucose,
g-glutamyltransferase, total-to–high-density-lipoprotein cholesterol ratio, 24-hour
albuminuria, and use of diuretics, inhibitors of the renin-angiotensin system
(b-blockers, angiotensin-converting enzyme inhibitors, and angiotensin type-1 receptor
blockers) and vasodilators (calcium-channel blockers and a-blockers). P values reflect
Bonferroni-corrected significance of the associations.
aP # 0.0001.
bP # 0.001.
cP < 0.05.
dP # 0.01. Figure 4. Receiver operating characteristic (ROC) curves for decline
in estimated glomerular ﬁltration rate (eGFR) from$ 60 to< 60 ml/min
per 1.73 m2. Using urinary mucin-1 (p8342) instead of 24-hour micro-
albuminuria to predict the decline of eGFR increased (P ¼ 0.011) the
AUC from 0.58 (95% CI ¼ 0.50–0.66) to 0.72 (95% CI ¼ 0.64–0.79).
CLINICAL RESEARCH Z-Y Zhang et al.: Mucin-1 as Urinary Biomarker of eGFR DeclineMicroalbuminuria is currently the standard for pre-
dicting progression to renal impairment. Mucin-1 was
the strongest peptidomic predictor in our analysis
(Figure 1, Table 3). Using urinary mucin-1 (p8342)
instead of 24-hour microalbuminuria (Figure 4) to pre-
dict eGFR decline from $ 60 to < 60 ml/min/1.73 m2
increased (P¼ 0.011) theAUC from 0.58 (95%CI¼ 0.50–
0.66) to 0.72 (95%CI¼ 0.64–0.79). Replacing the urinary
albumin-to-creatinine ratio by p8342 likewise increasedFigure 3. KaplanMeier survival function estimates for estimated
glomerular ﬁltration rate (eGFR) decline from $ 60 to < 60 ml/min
per 1.73 m2 by thirds of the mucin-1 subunit a (p8342) distribution.
The P value for the between-group differences was derived by the
log-rank test.
816(P ¼ 0.010) the AUC from 0.60 (95% CI ¼ 0.53–0.68) to
0.72 (95% CI ¼ 0.64–0.79). Adding urinary mucin-1 to
24-hour microalbuminuria or the albumin-to-creatinine
ratio increased (P # 0.0034) the AUCs to 0.72 (95%
CI ¼ 0.64–0.79) and 0.72 (95% CI ¼ 0.65–0.80), respec-
tively. In a sensitivity analysis, we additionally
considered baseline eGFR as predictor. For baseline eGFR
alone and eGFR combined with either urinary mucin-1
or 24-hour microalbuminuria, the AUCs were 0.81
(95% CI ¼ 0.76–0.87), 0.84 (95% CI ¼ 0.79–0.89), and
0.82 (95% CI¼ 0.77–0.87), respectively. Adding mucin-
1 to eGFR slightly but signiﬁcantly (P ¼ 0.05) increased
the AUC, whereas this was not the case for 24-hour
microalbuminuria (P ¼ 0.26).
DISCUSSION
A comprehensive literature search (see Supplementary
Material) did not reveal any population study in which
renal functionwas correlatedwith individual sequenced
urinary peptides. Our main ﬁndings can be summarized
as follows: (i) eGFR and change in eGFR over time were
inversely correlated with peptide fragments derived
from the mucin-1 subunit a, collagen I and III,
and ﬁbrinogen a-chain (Figure 1, Table 2, and
Supplementary Table S3); (ii) the relative risk of having
or progressing to eGFR < 60 ml/min/1.73 m2 was asso-
ciated with fragments from mucin-1 subunit a and
collagen I (Figure 1, Table 3, and Supplementary
Table S4); (iii) and PLS conﬁrmed the aforementioned
ﬁndings and identiﬁed a mucin-1 subunit a fragment asKidney International Reports (2017) 2, 811–820
Z-Y Zhang et al.: Mucin-1 as Urinary Biomarker of eGFR Decline CLINICAL RESEARCHthe strongest peptidomic correlate of a reduced eGFR
with a VIP score of 2.47, compared with a score of 1.80
for collagen I fragment p77763 as the next contender
(Figure 2). The most salient ﬁnding of our study was
therefore the identiﬁcation of the urinary mucin-1 sub-
unit a fragment as a correlate and predictor of renal
dysfunction in the general population.
Mucin-1, also known as Krebs von den Lungen6
antigen (KL-6), is a high-molecular-weight (400 kDa),
heavily O-glycosylated, type-I membrane-tethered
glycoprotein that, under normal conditions, is
expressed at the apical surface of epithelial cells.29 The
a-subunit of the protein consists of the N-terminus
(104 amino acids), a 20amino acid, variable-number,
tandem-repeat segment, which is repeated 25 to 125
times depending on genetic variation and splicing, and
a C-terminus of 170 amino acids.29 The a-subunit is
noncovalently bound to the transmembrane b-subunit,
which consists of a small extracellular region of 58
amino acids, a transmembrane region of 28 amino acids,
and a cytoplasmic tail of 72 amino acids.29 Normal
kidneys express mucin-1 in the thick segment of the
loop of Henle and in the distal tubules and collecting
ducts.30–32 Diabetic kidneys also express mucin-1 in
the thin segment of the loop of Henle and proximal
tubules and in parietal cells lining the Bowman space.30
The mucin-1 subunit a protrudes 200 to 500 nm above
the plasma membrane, far above all other membrane-
associated proteins within the 10-nm protective
glycocalyx.33
The main function of mucin-1 is to shield cell sur-
faces by maintenance of a luminal epithelial muco-
barrier.34 Mucin-1 is chemotactic for human
ﬁbroblasts35 but inhibits cellular binding to collagen I
and IV.29 The secreted mucin-1 isoform is a ligand for
the mucin-1 receptor and, upon binding, initiates
signal transduction.29 In mice, renal ischemia-perfusion
injury induced mucin-1 expression in all tubular
epithelia.36 The protein stimulates expression of
hypoxia-inducible transcription factors, which
orchestrate a protective response against acute kidney
injury.36 Our current observations are in line with
these experimental ﬁndings,36 the expression of mucin-
1 in renal endothelium and tubular epithelium29 as well
as its upregulation in diabetic kidneys.30 Recently
several investigators discovered a frameshift mutation
in the MUC1 gene, located on chromosome 1 (1q21).37
The mutation creates an abnormal sequence, encoding
a new peptide that accumulates inside the MUC1-
expressing renal tubular cells.38,39 It causes autosomal
dominant medullary cystic kidney disease type 1. The
clinical characteristics include progression to CKD,
with a widely variable age of onset of end-stage renal
disease, probably dependent on genegene and
Kidney International Reports (2017) 2, 811–820geneenvironment interactions,39 a bland urinary
sediment without blood and minimal protein, renal
ﬁbrosis, and cysts, but with no other organs expressing
mucin-1 being affected. The observation that affected
patients do not have proteinuria and the low preva-
lence of microalbuminuria in our study probably ex-
plains why p8432 was a better predictor of eGFR
decline than the urinary albumin-to-creatinine ratio or
24-hour microalbuminuria. Mutations in the uromo-
dulin gene (UMOD) cause medullary cystic kidney
disease type 2,34,40 which is characterized by juvenile
hyperuricaemia, frequent gout, and progressive CKD.
However, in our current study, eGFR was only weakly
associated with 4 uromodulin fragments, with VIP
scores ranging from 0.56 to 0.82.
Decline of renal function and renal ﬁbrosis are often
accompanied by a decrease in the urinary excretion of
collagen fragments.10,41 We observed that eGFR and
change in eGFR were bi-directionally associated with 2
collagen I fragments and in addition were inversely
associated with a collagen III fragment (Table 2,
Figures 1 and 2). Several mechanisms might explain
these bidirectional associations. Higher levels of tissue
inhibitor of matrix metalloproteinase type 1, as
observed in patients with renal dysfunction,42 might
inhibit the breakdown of collagen. If originating from
extrarenal sites, collagen fragments, depending on their
size, might either be insufﬁciently retained by
the glomerular sieve or fail to be reabsorbed in the
tubules.5,10,41 Finally, reactive overexpression of
mucin-1 in the tubular epithelium of patients with
early renal impairment might lead to less retention of
collagen fragments.29 Both eGFR and change in eGFR
were also inversely associated with the ﬁbrinogen a
chain (Table 2, Figures 1 and 2). Fibrinogen plays a role
in the pathogenesis of ﬁbrotic disorders by acting as a
proﬁbrotic ligand for a variety of cellular surface
receptors. In a murine model of renal interstitial
ﬁbrosis induced by obstruction of the ureter,43,44
pharmacological or genetic depletion of ﬁbrinogen
protected the kidneys against ﬁbrosis. In selected
patients with hypertensive nephropathy, the urinary
excretion of the ﬁbrinogen a chain was 15-fold
elevated compared with that in healthy controls and
was associated with a rapid decline in renal function
(6.7 ml/min/1.73 m2 per year).45
One potential limitation of the current study is that
urinary peptidomic biomarkers derived from collagen
originate not only from the kidney but from other
organs as well, including bone tissue and the heart.
However, urine is the matrix closest to the kidney.4 In
analyses adjusted for body height as an index of skel-
etal health46 or left ventricular dysfunction,47 our
ﬁndings were conﬁrmatory (data not shown). In our817
CLINICAL RESEARCH Z-Y Zhang et al.: Mucin-1 as Urinary Biomarker of eGFR Declineview, the aforementioned limitation does not apply to
p8342, because there is no association between mucin-1
levels in serum and urine,30 because renal tubular
cells express mucin-130–32 as a speciﬁc renoprotective
agent,30,36 and because genetic mutation of MUC1
cause tubulointerstitial ﬁbrosis.38,39 Furthermore, we
analyzed only the urinary peptides with a detectable
signal in more than 95% of the participants. Ignoring
biomarkers with missing values might waste poten-
tially important information, explaining why, in pre-
vious studies of a more exploratory nature, this
threshold was relaxed to 70%47 or lower.48 However,
as a major objective of the present study was to deepen
insight into the pathophysiological pathways leading
to renal injury in the general population, we chose to
apply a more stringent criterion, thereby avoiding the
possibility of false-positive ﬁndings. Finally, the pro-
portional hazard regression included only a subset of
558 participants (69.3%) who had both a baseline and
follow-up measurement and did not have a baseline
eGFR < 60 ml/min/1.73 m2.
In conclusion, shedding of the mucin-1 subunit a,
an extracellular protein expressed in renal tubular
epithelium, is a predictor of renal impairment and, in
the general population, outperforms other urinary
biomarkers, including collagen fragments and micro-
albumin. Elucidation of the underlying molecular
pathways in experimental studies might establish
mucin-1 as a novel urinary biomarker allowing the
early detection of renal dysfunction at a stage when
prevention of CKD remains an achievable option.
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